Viking Therapeutics (VKTX)
(Delayed Data from NSDQ)
$64.67 USD
-1.80 (-2.71%)
Updated Apr 18, 2024 04:00 PM ET
After-Market: $64.70 +0.03 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum D VGM
Brokerage Reports
0 items in cart
Viking Therapeutics, Inc. [VKTX]
Reports for Purchase
Showing records 1 - 20 ( 209 total )
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
First Drug Approval in NASH Helps Set Path in Navigating Regulatory Currents
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
With The Weight Loss Bar Getting Higher, Where Does Oral VK2735 Stand?
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
It''s Been a Wonderful Trip So Far as VENTURE Nails It; Target Upped to $90
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Weighing in on GLP-1: Unpacking Oral Drugs and MA Momentum; Gauging Viking''s Position in the Mix; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2023 Results; Key Upcoming Clinical Readouts Across Obesity and NASH Programs Set the Stage for 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We are updating our Healthcare coverage to reflect a recent analyst departure and to drop
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for VKTX 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Critical Near-Term Data Catalysts In Our Universe Represent Thesis Definers
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Smooth Sailing For VK2809; Updated Phase 2b VOYAGE Data Continue to Impress; Next Readout 1H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Drugs For Weight Loss Continue to Be Winners; We Think VK2735 Could Stake a Claim
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results; Metabolic Programs Dominate the Pipeline; VK2735 and Additional VOYAGE Data in 1H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology -Healthcare Coverage Update
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
High Demand and Interest Support Phase 2 VENTURE Enrollment Completion; Obesity Data in 1H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
New Phase 1 Readout Continues to Build VK2735 Favorable Metabolic Profile; Phase 2 VENTURE in Obesity Ongoing
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
VK2735 Cuts Through the Fat in ObesityWeek Presentation
Provider: Roth Capital Partners, Inc.
Analyst: DUPUIS D
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Going Big to Go Small; Phase 2 VENTURE Study of VK2735 in Obesity Begins
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MACE Benefits From SELECT Trial Read Through Positive to VK2735
Provider: Roth Capital Partners, Inc.
Analyst: DUPUIS D